David Melamed, PhD,  —

The U.S. Food and Drug Administration (FDA) has provided some recommendations to Saniona regarding the development of Tesomet to treat Prader-Willi syndrome (PWS). In particular, the agency is advising the company to conduct a Phase 3 trial to follow the planned Phase 2b clinical trial, as well…

Researchers in Russia have published the first detailed description of a prenatal Prader-Willi syndrome (PWS) diagnosis based on the results of a noninvasive genetic test. The study, “Prenatal diagnosis of Prader‐Willi syndrome due to uniparental disomy with NIPS: Case report and literature review,” was published in…

The U.S. Food and Drug Administration (FDA) gave positive feedback to Saniona regarding its work to advance Tesomet as a possible treatment to aid weight loss in people with Prader-Willi syndrome (PWS). Saniona now expects to file an investigational new drug (IND) application, asking to…